View : 258 Download: 480

Full metadata record

DC Field Value Language
dc.contributor.author이한길*
dc.date.accessioned2026-04-06T16:30:02Z-
dc.date.available2026-04-06T16:30:02Z-
dc.date.issued2026*
dc.identifier.issn0815-9319*
dc.identifier.otherOAK-39161*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/274999-
dc.description.abstractBackground and Aim: Potassium-competitive acid blockers (P-CABs) are a novel class of acid suppressants developed to overcome the limitations of proton pump inhibitors (PPIs), providing rapid and sustained acid suppression. While PPI-related adverse events (AEs) are well-documented, safety data on P-CABs remain limited. This study systematically reviewed AEs of P-CABs compared with PPIs, with a meta-analysis focusing on hypergastrinemia. Methods: Following a preregistered PROSPERO protocol (CRD42024565011), we searched for randomized controlled trials (RCTs) and observational studies comparing P-CABs and PPIs in patients with gastroesophageal reflux disease or peptic ulcer disease. Frequently reported AEs and serious AEs (SAEs) were qualitatively synthesized; hypergastrinemia was quantitatively analyzed using a random-effects model. Results: Ten RCTs and one observational study were included. Nine studies reported specific AEs, with diarrhea reported in seven studies and constipation, nasopharyngitis, and liver-related events, each reported in three. Most AEs had reporting rates below 5%, except diarrhea, nasopharyngitis, and upper respiratory tract inflammation, which exceeded 5% in both groups. Fracture demonstrated the largest relative difference between the groups, with a threefold higher rate in the P-CAB group. SAEs were observed in fewer than 10% of patients in both groups in most studies. A meta-analysis of six studies showed greater serum gastrin elevation in the P-CAB group compared with the PPI group (mean difference: 130.92 pg/mL, 95% confidence intervals: 36.37–225.47). Conclusions: P-CABs demonstrate a comparable AE risk to PPIs but monitoring for hypergastrinemia and hepatic dysfunction is essential. Further research is required to support safer clinical use. © 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.*
dc.description.sponsorshipJohn Wiley and Sons Inc*
dc.languageEnglish*
dc.subjectgastroesophageal reflux disease*
dc.subjectmeta-analysis*
dc.subjectpotassium-competitive acid blockers*
dc.subjectproton pump inhibitors*
dc.subjectsystematic review*
dc.titleSafety of Potassium-Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta-Analysis*
dc.typeReview*
dc.relation.issue1*
dc.relation.volume41*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage28*
dc.relation.lastpage40*
dc.relation.journaltitleJournal of Gastroenterology and Hepatology (Australia)*
dc.identifier.doi10.1111/jgh.70178*
dc.identifier.wosidWOS:001629135600001*
dc.identifier.scopusid2-s2.0-105023881593*
dc.author.googleJang Y.*
dc.author.googlePark J.*
dc.author.googleKang D.*
dc.author.googleKim J.*
dc.author.googleChoi H.*
dc.author.googleJeon H.-L.*
dc.author.googleLee H.*
dc.contributor.scopusid이한길(56802870700)*
dc.date.modifydate20260818161659*


qrcode

BROWSE